Literature DB >> 7542815

The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique.

P Strumph1, D Kirsch, W Gooding, P Carroll.   

Abstract

We studied seven nondiabetic subjects with the autoimmune diseases psoriasis, multiple sclerosis, and primary biliary sclerosis who were to receive FK506 as experimental immunotherapy. All subjects underwent two standard oral glucose tolerance tests and two 180-min hyperglycemic clamps immediately before and 10 weeks after starting FK506. There was no significant difference in weight or HbA1c pre- vs. post-FK506 treatment. FK506 levels were therapeutic and non-toxic (0.1-1 ng/ml) for all subjects studied. Repeated measures analysis of variance for interaction between time and treatment was performed on insulin (after outlier removed) and glucose values from the OGTT. There was neither time-by-treatment interaction, nor a treatment effect (P > 0.1). There were no significant differences in pre- vs. post-FK506 treatment values of plasma glucose during the hyperglycemic clamp mean acute insulin response to glucose (AIRG) 164 +/- 38 pmol/L vs. 148 +/- 46 pmol/L (P > 0.1); mean incremental area under the insulin curve (IAUC) during the first 10 min of the study, 473 +/- 109 pmol/L vs. 443 +/- 146 pmol/L (P > 0.1); total area under the insulin curve (TAUC) during the first 10 min of the study, 786 +/- 152 pmol/L vs. 781 +/- 18 pmol/L (P > 0.1); mean glucose infusion rate (GIR) 37.7 +/- 5.0 mumol/kg/min vs. 33.3 +/- 4.4 mumol/kg/min (P > 0.1); or mean insulin sensitivity index (ISI), 3.05 +/- 0.4 vs. 3.13 +/- 0.5 (P > 0.1). Mean steady-state insulin secretion (SSI) was significantly lower 244 +/- 43 pmol/L vs. 200 +/- 25.2 pmol/L (P = 0.03). Peak first-phase insulin secretion values of 321 +/- 62 pmol/L vs. 263 +/- 57 pmol/L approached significance (P = 0.07). No patient progressed to diabetes during the study. FK506 decreased steady-state insulin secretion during the last 60 min of the clamp, regardless of initial glucose tolerance. Insulin sensitivity and glucose infusion rate did not change in the group as a whole with FK506 treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542815

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.

Authors:  Lara Aygen Øzbay; Niels Møller; Claus Juhl; Mette Bjerre; Jan Carstens; Jørgen Rungby; Kaj Anker Jørgensen
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

2.  Long-term results of pancreas transplantation under tacrolius immunosuppression.

Authors:  M L Jordan; R Shapiro; H A Gritsch; F Egidi; A Khanna; C A Vivas; V P Scantlebury; J J Fung; T E Starzl; R J Corry
Journal:  Transplantation       Date:  1999-01-27       Impact factor: 4.939

Review 3.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.

Authors:  Tatiana Froud; David A Baidal; Raquel Faradji; Pablo Cure; Davide Mineo; Gennaro Selvaggi; Norma S Kenyon; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2008-12-27       Impact factor: 4.939

5.  Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.

Authors:  Pieter Gillard; Robert Hilbrands; Ursule Van de Velde; Zhidong Ling; Da Hae Lee; Ilse Weets; Frans Gorus; Christophe De Block; Leonard Kaufman; Chantal Mathieu; Daniel Pipeleers; Bart Keymeulen
Journal:  Diabetes Care       Date:  2013-09-16       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.